Granite Point Capital Management L.P. decreased its position in Rubius Therapeutics Inc (NASDAQ:RUBY) by 69.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,848 shares of the company’s stock after selling 81,852 shares during the quarter. Granite Point Capital Management L.P.’s holdings in Rubius Therapeutics were worth $593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Rubius Therapeutics in the 3rd quarter worth approximately $38,155,000. ARK Investment Management LLC bought a new stake in Rubius Therapeutics in the 3rd quarter worth approximately $4,518,000. Marshall Wace North America L.P. purchased a new position in shares of Rubius Therapeutics in the 3rd quarter worth approximately $1,405,000. Jennison Associates LLC purchased a new position in shares of Rubius Therapeutics in the 3rd quarter worth approximately $11,333,000. Finally, Baillie Gifford & Co. purchased a new position in shares of Rubius Therapeutics in the 3rd quarter worth approximately $93,831,000. 81.24% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have recently commented on the company. Zacks Investment Research cut Rubius Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 30th. ValuEngine cut Rubius Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Finally, Morgan Stanley dropped their target price on Rubius Therapeutics from $37.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, December 19th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $30.00.
Rubius Therapeutics (NASDAQ:RUBY) last announced its earnings results on Tuesday, November 13th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.06). As a group, analysts predict that Rubius Therapeutics Inc will post -1.75 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Granite Point Capital Management L.P. Trims Holdings in Rubius Therapeutics Inc (RUBY)” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2019/02/11/granite-point-capital-management-l-p-trims-holdings-in-rubius-therapeutics-inc-ruby.html.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Featured Article: What Does Beta Mean In Stock Selection
Want to see what other hedge funds are holding RUBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rubius Therapeutics Inc (NASDAQ:RUBY).
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.